Compare Bristol-Myers Squibb Co (BMY) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Costco Wholesale Corporation — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Costco Wholesale Corporation trades at $921.58 (market cap $408.78B). The key difference: Costco Wholesale Corporation is far larger — about 3.5× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | COST | |
|---|---|---|
Market Cap | $116.30B | $408.78B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $1.09K |
52-Week Low | $42.60 | $849.63 |
Enterprise Value | $152.24B | $396.92B |
Dividend Yield | 4.42% | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Costco (COST) trades at $926.43, up 1.11% with strong fundamentals including 11.3% March sales growth and consistent earnings beats. The stock faces technical headwinds with bearish moving averages but maintains solid profitability with $8.1B net income and expanding margins. Recent membership fee increases and warehouse expansion support long-term growth, though high valuation multiples present near-term pressure.
Outlook remains positive with analyst consensus at $1,120 price target (65% buy ratings), but investors should monitor valuation sustainability amid technical weakness. Key risks include competitive pressures and economic sensitivity, while institutional accumulation and strong cash flow generation provide fundamental support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
